# CARTITUDE-1 (NCT03548207)

> A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03548207
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: JNJ-68284528
- Enrollment: 126
- Primary outcome: Phase 1b: Number of Participants With Adverse Events as Per Severity
- Primary outcome: Phase 2: Overall Response Rate (ORR)

## Commentary we found

- YouTube: 164
- X threads: 100
- Podcasts: 68
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=cartitude-1-nct03548207

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03548207", "email": "<work email>"}; the inbox owner confirms by the emailed link.